NASDAQ
DMIIU
Last Price
US $10.2
Valuation
Financial
Performance
Cash flow to debt coverage
Drugs Made In America Acquisition II Corp. Unit balance-sheet data unavailable; cash-flow debt coverage cannot be computed.
Free cash flow growth
Drugs Made In America Acquisition II Corp. Unit has insufficient data to evaluate this check.
Debt-to-equity ratio
Drugs Made In America Acquisition II Corp. Unit has insufficient data to evaluate this check.
Debt-to-equity trend
Drugs Made In America Acquisition II Corp. Unit has insufficient data to evaluate this check.
Net debt to EBITDA
Drugs Made In America Acquisition II Corp. Unit has negative EBITDA, making leverage ratio unreliable
Interest coverage
Drugs Made In America Acquisition II Corp. Unit interest expense data unavailable for the most recent period; interest coverage ratio cannot be reliably computed.
Profit margin growth
Drugs Made In America Acquisition II Corp. Unit has insufficient data to evaluate this check.
Current ratio
Drugs Made In America Acquisition II Corp. Unit has insufficient data to evaluate this check.
Return on assets
Drugs Made In America Acquisition II Corp. Unit's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
Drugs Made In America Acquisition II Corp. Unit's return on equity of 0.00%, is lower than 15.00%, indicating bad performance
Earnings quality
Drugs Made In America Acquisition II Corp. Unit has insufficient data to evaluate this check.
Earnings stability
Drugs Made In America Acquisition II Corp. Unit has insufficient public price history to evaluate earnings stability.
Positive free cash flow
Drugs Made In America Acquisition II Corp. Unit has negative free cash flow, indicating the company is burning cash rather than generating it
Free cash flow yield
Drugs Made In America Acquisition II Corp. Unit has a free cash flow yield of 0.00%, which is below the 2.00% threshold, indicating limited cash return relative to market value
Earnings growth
Drugs Made In America Acquisition II Corp. Unit has insufficient data to evaluate this check.
Revenue growth
Drugs Made In America Acquisition II Corp. Unit has insufficient data to evaluate this check.
Return on invested capital
ROIC is unavailable for Drugs Made In America Acquisition II Corp. Unit; this check cannot be evaluated.
3-year revenue CAGR
Drugs Made In America Acquisition II Corp. Unit has insufficient revenue history to calculate 3-year revenue CAGR.
Revenue consistency
Drugs Made In America Acquisition II Corp. Unit has insufficient public price history to evaluate revenue consistency.
Return on equity consistency
Drugs Made In America Acquisition II Corp. Unit has insufficient public price history to evaluate ROE consistency.
Base Cash Flow Valuation (DCF)
Drugs Made In America Acquisition II Corp. Unit has insufficient data to evaluate this check.
Earnings yield (TTM)
Drugs Made In America Acquisition II Corp. Unit has insufficient data to evaluate this check.
Base EBITDA Valuation
Drugs Made In America Acquisition II Corp. Unit is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model
EV/EBITDA (FY)
Drugs Made In America Acquisition II Corp. Unit has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
Drugs Made In America Acquisition II Corp. Unit has insufficient data to calculate the PEG ratio.
Price-to-book ratio (FY)
Drugs Made In America Acquisition II Corp. Unit has negative shareholder equity; price-to-book is not meaningful and the check fails
Price-to-sales ratio (TTM)
Drugs Made In America Acquisition II Corp. Unit has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-
Return on equity
ROIC: -
Valuation History
-
Price to Earnings
EV/EBITDA: -
Cash flow
Profit margin
-
Fair Value
Market $10.2
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.